Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 3/20 | 0.43 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.43 |
| ▸ | TYK2 | P29597 | 9/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.35 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20091681 | 0.94 | SLC9A1 (0.44) | SLC9A1SLC9A2TYK2CNR2ALDH1A1 | |
| SCHEMBL23638031 | 0.88 | TYK2 (0.36) | SLC9A1SLC9A2TYK2ALDH1A1ACMSD | |
| SCHEMBL20092549 | 0.79 | TYK2 (0.41) | TYK2ALDH1A1 | |
| SCHEMBL20093001 | 0.78 | TYK2 (0.38) | TYK2ACMSDDRD2DRD3 | |
| SCHEMBL20073679 | 0.77 | TYK2 (0.36) | TYK2ALDH1A1HPGD | |
| SCHEMBL20073681 | 0.76 | DRD2 (0.39) | TYK2ACMSDDRD2DRD3 | |
| SCHEMBL27672300 | 0.75 | LMNA (0.36) | ALDH1A1ACMSD | |
| SCHEMBL20155988 | 0.73 | HSD11B1 (0.32) | SLC9A1SLC9A2HSD11B1 | |
| SCHEMBL20073696 | 0.71 | QDPR (0.44) | ALDH1A1 | |
| SCHEMBL13544340 | 0.71 | ACMSD (0.56) | TYK2ALDH1A1ACMSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10323036-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-20180155349-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-07 | — | — | US | disclosed |
| US-20180155349-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-07 | — | — | US | disclosed |
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10323036-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | SLC9A1 4806/4885SLC9A2 4741/4885TYK2 1/4885 |
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | SLC9A1 4806/4885SLC9A2 4741/4885TYK2 1/4885 |
| US-20180155349-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | SLC9A1 4806/4885SLC9A2 4741/4885TYK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.